Systemic capillary leak syndrome (SCLS)
Conditions for which IVIg use is in exceptional circumstances only

<table>
<thead>
<tr>
<th>Specific Conditions</th>
<th>Systemic capillary leak syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level of Evidence</td>
<td>Insufficient data (Category 4a)</td>
</tr>
</tbody>
</table>

SCLS is an extremely rare condition that is characterised by life-threatening attacks of reversible capillary hyperpermeability, accompanied by haemoconcentration and hypoalbuminaemia.

A diagnosis by a consultant physician, emergency specialist or intensive care unit specialist is required.

Other therapies may be appropriate.

Approval will be provided for an initial period of 12 months only.

Clinicians requesting ongoing intravenous immunoglobulin (IVIg) therapy after the initial 12-month period are required to confirm in writing that the patient experienced a reduced number of severe episodes requiring hospital admission when treated with IVIg.

Maximum dose of 1–2 g/kg per month.

Refer to the current product information sheet for further information.

The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient.

Bibliography


Generated on: 23 February 2016